article thumbnail

Our Favorite Sales Blog Posts From 2018

CloserIQ

2018 has been an amazing year for all of us at CloserIQ , and we can’t believe we’re just a few days away from welcoming another one. Here are 20+ of our favorite sales blogs from 2018. In an industry full of numbers and data, a healthy competition can be the key to get your sales team performing.

Sales 79
article thumbnail

470% price increases

World of DTC Marketing

Humira’s net price—which subtracts discounts and rebates—increased by 110% between 2009 and 2018, from $16,663 per year to $35,041 per year. AbbVie’s internal documents show that from 2015 to 2018, senior executive bonuses were tied directly to Humira’s net revenue, allowing them to profit from AbbVie’s price increases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

One company, Amgen, spent nearly six times as much on buybacks, dividends, and executive compensation as it did on R&D in 2018. Many drug companies spent a significant portion of their R&D budget on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research.

Pharma 292
article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

Those health insurers, in turn, use the discounts to offer more competitive premiums in a bid to attract enrollees. Drug non-adherence cost the country at least $495 billion and contributed to over 275,000 premature deaths in 2016, according to a 2018 study in The Annals of Pharmacotherapy. It isn’t very likely.

Insurance 226
article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

percent from 2018. The cost of bringing a drug to market decreased from $2,168 million in 2018 to $1,981 in 2019. So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1

Pharma 187
article thumbnail

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

Eversana Intouch

By 2018, that share had fallen by about half. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled. Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline.

Pharma 105
article thumbnail

Our Best of 2018- to Fuel Your Best 2019

Integrity Solutions

Here is some of our ‘Best of 2018’ content that can help fuel thoughts, discussions and strategies to make 2019 your best year yet. They have become increasingly more important- even becoming a competitive differentiator. Our most-read blog of 2018 was this one by Joyce Hames.